{"altmetric_id":8419313,"counts":{"readers":{"mendeley":5,"citeulike":0,"connotea":0},"total":{"posts_count":1},"wikipedia":{"unique_users_count":1,"unique_users":["en:50694916"],"posts_count":1}},"citation":{"altmetric_jid":"4f6fa6173cf058f6100073c5","authors":["Atul Tiwari"],"doi":"10.1517\/13543784.14.11.1359","endpage":"1372","first_seen_on":"2016-06-01T13:29:13+00:00","issns":["1354-3784","1744-7658"],"issue":"11","journal":"Expert Opinion on Investigational Drugs","last_mentioned_on":1464787403,"links":["http:\/\/dx.doi.org\/10.1517\/13543784.14.11.1359"],"pmid":"16255676","pubdate":"2005-11-15T00:00:00+00:00","publisher_subjects":[{"name":"Pharmacology And Pharmaceutical Sciences","scheme":"era"}],"scopus_subjects":["Health Sciences","Medicine","Life Sciences","Pharmacology, Toxicology and Pharmaceutics"],"startpage":"1359","subjects":["drugtherapy"],"title":"Benign prostatic hyperplasia: an insight into current investigational medical therapies","type":"article","volume":"14","mendeley_url":"http:\/\/www.mendeley.com\/research\/benign-prostatic-hyperplasia-insight-current-investigational-medical-therapies"},"altmetric_score":{"score":3,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":3},"context_for_score":{"all":{"total_number_of_other_articles":7842728,"mean":6.6456077751988,"rank":1924619,"this_scored_higher_than_pct":61,"this_scored_higher_than":4835299,"rank_type":"exact","sample_size":7842728,"percentile":61},"similar_age_3m":{"total_number_of_other_articles":269347,"mean":11.365084590081,"rank":85943,"this_scored_higher_than_pct":66,"this_scored_higher_than":179502,"rank_type":"exact","sample_size":269347,"percentile":66},"this_journal":{"total_number_of_other_articles":810,"mean":2.1419208899876,"rank":139,"this_scored_higher_than_pct":67,"this_scored_higher_than":543,"rank_type":"exact","sample_size":810,"percentile":67},"similar_age_this_journal_3m":{"total_number_of_other_articles":34,"mean":0.83636363636364,"rank":2,"this_scored_higher_than_pct":94,"this_scored_higher_than":32,"rank_type":"exact","sample_size":34,"percentile":94}}},"demographics":{"users":{"mendeley":{"by_status":{"Librarian":1,"Researcher":2,"Other":1,"Student  > Bachelor":1},"by_discipline":{"Medicine and Dentistry":3,"Chemistry":1,"Arts and Humanities":1}}}},"posts":{"wikipedia":[{"title":"Cioteronel","url":"http:\/\/en.wikipedia.org\/?diff=prev&oldid=723172667#altmetric_citation_e11105f7-3713-4447-92a0-b54493a94e9b","license":"public","citation_ids":[8419313],"posted_on":"2016-06-01T13:23:23+00:00","summary":"Cioteronel (INN, USAN) (developmental code name CPC-10997; former tentative brand names Cyoctol, Ethocyn, X-Andron) is a non-steroidal antiandrogen that was never marketed.","page_url":"http:\/\/en.wikipedia.org\/?curid=50694916","wiki_lang":"en","author":{"name":"Medgirl131","url":"http:\/\/en.wikipedia.org\/wiki\/User:Medgirl131"}}]}}